NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

West SL, Garbutt JC, Carey TS, et al. Pharmacotherapy for Alcohol Dependence. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 Jan. (Evidence Reports/Technology Assessments, No. 3.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Pharmacotherapy for Alcohol Dependence

Pharmacotherapy for Alcohol Dependence.

Show details


  1. Ades J, Lejoyeux M Clinical evaluation of acamprosate to reduce alcohol intake. Alcohol Alcohol Suppl. 1993;2:275–8. [PubMed: 7748311]
  2. Agosti V The efficacy of controlled trials of alcohol misuse treatments in maintaining abstinence: a meta-analysis. Int J Addict. 1994;29(6):759–69. [PubMed: 8034384]
  3. Aharan CH, Ogilvie RD, Partington JT Clinical indications of motivation in alcoholic patients. Q J Stud Alcohol. 1967;28(3):486–92. [PubMed: 6048610]
  4. Aliyev NN Trial of interferon in chronic alcoholism. Psychiatry Res. 1994;54(3):307–8. [PubMed: 7792335]
  5. Allen JP, Litten RZ, Fertig JB NIDA-NIAAA workshop: efficacy of therapies in drug and alcohol addiction. Strategies for treatment of alcohol problems. Psychopharmacol Bull. 1995;31(4):665–9. [PubMed: 8851638]
  6. Altman J, Everitt BJ, Glautier S, Markou A, Nutt D, Oretti R, Phillipps GD, Robbins TW The biological, social and clinical bases of drug addiction: commentary and debate. Psychopharmacol. 1996;125(4):285–345. [PubMed: 8826538]
  7. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 4th ed.Washington: American Psychiatric Association; 1994.
  8. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 3rd ed, rev.Washington: American Psychiatric Association; 1987.
  9. American Psychiatric Association Diagnostic and statistical manual of mental disorders, 3rd ed.Washington: American Psychiatric Association; 1980.
  10. American Psychiatric Association Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Association; 1952.
  11. Anonymous A new drug against alcoholism. Pharmazeutische Zeitung. 1995;140(48):–.
  12. Anonymous Acamprosate for alcohol dependence. Hosp Pract. 1996;31(9):–.
  13. Anonymous Acamprosate helps maintain abstinence from alcohol after detoxification. Drugs Therapy Pers. 1997;10(5):1–5.
  14. Anonymous Acamprosate. Prescrire Int. 1997;6(28):42–3.
  15. Anonymous Bromocriptine for alcohol dependence. Hosp Pract. 1995;30(6):–.
  16. Anonymous Disulfiram (Antabuse) Medical Let Drugs Ther. 1980;22(1):1–2.
  17. Anonymous Disulfiram treatment of alcoholism. JAMA. 1987;257(7):926–7. [PubMed: 3543416]
  18. Anonymous Disulfiram treatment of alcoholism [correction] Am J Med. 1991;91(4):–.
  19. Anonymous Naltrexone approved as adjunct in alcoholism treatment. JAMA. 1995;273(8):–.
  20. Anonymous Naltrexone for alcohol dependence. Med Let Drugs Ther. 1995;37(953):64–6. [PubMed: 7603392]
  21. Anonymous Ritanserin. Drugs Future. 1996;21(5):–.
  22. Anton RF Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol Alcohol. 1996;31:43–53. [PubMed: 8737000]
  23. Anton RF New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res. 1996;20:3A–9A. [PubMed: 8904988]
  24. Anton RF Pharmacotherapy of alcoholism -- 10 years of progress. Alcohol Clin Exp Res. 1996;20:172A–5A. [PubMed: 8947259]
  25. Anton RF, Moak DH, Latham PK The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53(3):225–31. [PubMed: 8611059]
  26. Aubin H-J, Lehert P, Beaupere B, Parot P, Barrucand D Tolerability of the combination of acamprosate with drug used to prevent alcohol withdrawal syndrome. Alcoholism. 1995;31(1-2):25–38.
  27. Azrin NH Improvements in the community-reinforcement approach to alcoholism. Behav Res Therapy. 1976;14(5):339–48. [PubMed: 971207]
  28. Azrin NH, Sisson RW, Meyers R, Godley M Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry. 1982;13(2):105–12. [PubMed: 7130406]
  29. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49:599–608. [PubMed: 1637250]
  30. Baekeland F, Lundwall L, Kissin B, Shanahan T Correlates of outcome in disulfiram treatment of alcoholism. J Nerv Mental Dis. 1971;153(1):1–9. [PubMed: 4936190]
  31. Balldin J, Berggren U, Bokstrom K, Eriksson M, Gottfires CG, Karlsson I, Walinder J Six-month open trial with zimelidine in alcohol-dependent patients: reduction in days of alcohol intake. Drug Alcohol Depend. 1994;35(3):245–8. [PubMed: 7956755]
  32. Balldin J, Berggren U, Engel J, Eriksson M Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking. Alcohol Clin Exp Res. 1994;18(4):822–5. [PubMed: 7978090]
  33. Balldin J, Berggren U, Engel J, Eriksson M, Hard E, Soderpalm B Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res. 1994;18(5):1133–6. [PubMed: 7847595]
  34. Batel P The treatment of alcoholism in France. Drug Alcohol Depend. 1995;39:S15–21. [PubMed: 8565793]
  35. Berg BJ, Pettinati HM, Volpicelli JR A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf. 1996;15(4):274–82. [PubMed: 8905252]
  36. Beyeler C, Fisch HU, Preisig R [Cardiovascular and metabolic changes in the Antabuse-alcohol reaction: basis for the diagnosis of degree of severity]. [German] Schweiz Med Wochenschr. 1987;117(2):52–60. [PubMed: 3544209]
  37. Bickel WK, Rizzuto P, Zielony RD, Klobas J, Pangiosonlis P, Mernit R, Knight WF Combined behavioral and pharmacological treatment of alcoholic methadone patients. J Subst Abuse. 1988-1989;1(2):161–71. [PubMed: 2980867]
  38. Bischof T, Bucher J, Battig B, Frei A [Disulfiram in the treatment of alcoholic patients]. [German] Schweiz Rundsch Med Prax. 1995;84(23):698–702.
  39. Bohme K, Piltz E [Is disulfiram treatment still indicated today]? [German] Dtsch Med Wochenschr. 1974;99(28):1492–6. [PubMed: 4212692]
  40. Bohn MJ, Kranzler HR, Beazoglou D, Staehler B Naltrexone and brief counseling to reduce heavy drinking: results of a small clinical trial. Am J Addict. 1994;3(2):91–9.
  41. Boland FJ, Mellor CS, Revusky S Chemical aversion treatment of alcoholism: lithium as the aversive agent. Behav Res Therapy. 1978;16(6):401–9. [PubMed: 736874]
  42. Borg V Bromocriptine in the prevention of alcohol abuse. Acta Psychiatr Scand. 1983;68(2):100–10. [PubMed: 6624506]
  43. Borup C, Kaiser A, Jensen E Long-term Antabuse treatment: tolerance and reasons for withdrawal. Acta Psychiatr Scand Suppl. 1992;86(369):47–9. [PubMed: 1471552]
  44. Borup C, Unden M Combined fluoxetine and disulfiram treatment of alcoholism with comorbid affective disorders. A naturalistic outcome study, including quality of life measurements. Eur Psychiatry. 1994;9(2):83–9.
  45. Bowens BJ, McBride WJ 5-HT2A receptor modulation of basal and ethanol-stimulated dopamine release in the posterior nucleus accumbens. Alcohol Clin Exp Res. 1997;21(3):–.
  46. Brady KT, Sonne SC, Roberts JM Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 1995;56(11):502–5. [PubMed: 7592501]
  47. Branchey L, Davis W, Lee KK, Fuller RK Psychiatric complications of disulfiram treatment. Am J Psychiatry. 1987;144(10):1310–2. [PubMed: 3310670]
  48. Brewer C Patterns of compliance and evasion in treatment programmes which include supervised disulfiram. Alcohol Alcohol. 1986;21(4):385–8. [PubMed: 3814254]
  49. Brewer C Recent developments in disulfiram treatment. Alcohol Alcohol. 1993;28(4):383–95. [PubMed: 8397520]
  50. Brewer C, Hardt F, Petersen EN Antabuse: experiences from 40 years of clinical use and the discovery of an active metabolite. Acta Psychiatr Scand Suppl. 1992;86(369):1–72.
  51. Brewer C, Smith J Probation linked supervised disulfiram in the treatment of habitual drunken offenders: results of a pilot study. Br Med J Clin Res Ed. 1983;287(6401):1282–3. [PMC free article: PMC1549690] [PubMed: 6416370]
  52. Browne-Mayers AN, Seelye EE, Brown DE Reorganized alcoholism service. Two years after. JAMA. 1973;224(2):233–5. [PubMed: 4739494]
  53. Bruguera M, Pares A, Heredia D, Rodes J Cyanamide hepatotoxicity. Incidence and clinico-pathological features. Liver. 1987;7(4):216–22. [PubMed: 3683093]
  54. Bruno F Buspirone in the treatment of alcoholic patients. Psychopathology. 1989;22:49–59. [PubMed: 2657838]
  55. Burroughs AK, Morgan MY, Sherlock S Double-blind controlled trial of bromocriptine, chlordiazepoxide and chlormethiazole for alcohol withdrawal symptoms. Alcohol Alcohol. 1985;20(3):263–71. [PubMed: 3902038]
  56. Butler D, Messiha FS Alcohol withdrawal and carbamazepine. Alcohol. 1986;3(2):113–29. [PubMed: 2872902]
  57. Caetano R, Tam TW Prevalence and correlates of DSM-IV and ICD-10 alcohol dependence. 1990 U.S. National Alcohol Survey. Alcohol Alcohol. 1995;30(2):177–86. [PubMed: 7662036]
  58. Carboni E, Acquas E, Frau R, DiChiara G Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol. 1989;164:515–9. [PubMed: 2767122]
  59. Carey-Smith KA, Joll TA, Nyoni VS, Irvine BL Assessment of intramuscular emulsified disulfiram in alcoholics by estimation of urinary diethylamine. J Stud Alcohol. 1988;49(6):571–5. [PubMed: 3070179]
  60. Caster DU The treatment of the recidivist alcoholic. Alcohol Clin Exp Res. 1977;1(1):87–90. [PubMed: 201178]
  61. Caster DU, Parsons OA Locus of control in alcoholics and treatment outcome. J Stud Alcohol. 1977;38(11):2087–95. [PubMed: 592833]
  62. Chick J Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol. 1995;30(6):785–7. [PubMed: 8679020]
  63. Chick J The efficacy of treatments in reducing alcohol consumption: a meta-analysis. Subst Use Misuse. 1996;31(9):–. [PubMed: 8853230]
  64. Chick J, Erickson CK Conference summary; Consensus Conference on Alcohol Dependence and the Role of Pharmacotherapy in its Treatment. Alcohol Clin Exp Res. 1996;20(2):391–402. [PubMed: 8730235]
  65. Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84–9. [PubMed: 1638335]
  66. Christensen JK Side-effects after Antabuse -- myths or reality? Br J Clin Pract Symp Supp. 1984;36:21–8. [PubMed: 6437426]
  67. Christensen JK, Ronsted P, Vaag UH Side effects after disulfiram. Comparison of disulfiram and placebo in a double-blind multicentre study. Acta Psychiatr Scand. 1984;69(4):265–73. [PubMed: 6372372]
  68. Ciraulo DA, Barnhill JG, Ciraulo AM, Sarid-Segal O, Knapp C, Greenblatt DJ, Shader RI Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Pharmacol. 1997;37(1):64–73. [PubMed: 9048275]
  69. Clark DC, Fawcett J Does lithium carbonate therapy for alcoholism deter relapse drinking? Recent Dev Alcohol. 1989;7:315–28. [PubMed: 2494686]
  70. Cloninger CR Neurogenetic adaptive mechanisms in alcoholism. Science. 1987;236:410–6. [PubMed: 2882604]
  71. Colgan A A pilot study of anafranil in the treatment of phobic states. Scott Med J. 1975;20:55–60. [PubMed: 1154016]
  72. Coppen A, Noguera R, Bailey J, Burns BH, Swani MS, Hare EH, Gardner R, Maggs R Prophylactic lithium in affective disorders. Controlled trial. Lancet. 1971;2(7719):275–9. [PubMed: 4104974]
  73. Cornelius JR, Salloum IM, Cornelius MD, Perel JM, Ehler JG, Jarrett PJ, Levin RL, Black A, Mann JJ Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull. 1995;31(2):297–303. [PubMed: 7491382]
  74. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, Perel JM, Thase ME Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol Bull. 1997;33(1):165–70. [PubMed: 9133770]
  75. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54(8):700–5. [PubMed: 9283504]
  76. Corrigan FM, Besson JA, Ward NI Red cell caesium, lithium and selenium in abstinent alcoholics. Alcohol Alcohol. 1991;26(3):309–14. [PubMed: 1930363]
  77. Costello RM Alcoholism treatment and evaluation: in search of methods. II. Collation of two-year follow-up studies. Int J Addict. 1975;10(5):857–67. [PubMed: 1176237]
  78. Critchfield GC, Eddy DM A confidence profile analysis of the effectiveness of disulfiram in the treatment of chronic alcoholism. Med Care. 1987;25:S66–75. [PubMed: 3323686]
  79. Croop RSM, Faulkner EB, Labriola DFP The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130–5. [PubMed: 9400350]
  80. Dahlgren L, Willander A Are special treatment facilities for female alcoholics needed? A controlled 2-year follow-up study from a specialized female unit (EWA) versus a mixed male/female treatment facility. Alcohol Clin Exp Res. 1989;13(4):499–504. [PubMed: 2679204]
  81. Dayhoff DA, Pope GC, Huber JG State variations in public and private alcoholism treatment at specialty substance abuse treatment facilities. J Stud Alcohol. 1994;55(5):549–60. [PubMed: 7990465]
  82. de la Fuente JR, Morse RM, Niven RG, Ilstrup DM A controlled study of lithium carbonate in the treatment of alcoholism. Mayo Clin Proc. 1989;64(2):177–80. [PubMed: 2493536]
  83. de Mari M, De Blasi R, Lamberti P, Carella A, Ferrari E Unilateral pallidal lesion after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord. 1993;8(2):247–9. [PubMed: 8474509]
  84. de Oliveira IR, da Rocha FP, Pereira EL, Miranda A de A, Ribeiro MG, Melo A Combined carbamazepine-buspirone treatment of alcohol dependence. J Clin Psychiatry. 1993;42(12):–. [PubMed: 8276740]
  85. Del Boca FK, Kranzler HR, Brown J, Korner PF Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20(8):1412–7. [PubMed: 8947318]
  86. Delgrange T, Khater J, Capron D, Duron B, Capron JP [Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis]. [French] Gastroenterol Clin Biol. 1992;16(8-9):687–91. [PubMed: 1426825]
  87. Dongier M, Vachon L, Schwartz G Bromocriptine in the treatment of alcohol dependence. Alcohol Clin Exp Res. 1991;15(6):970–7. [PubMed: 1789393]
  88. Dorus W, Ostrow DG, Anton R, Cushman P, Collins JF, Schaefer M, Charles HL, Desai P, Hayashida M, Malkerneker U, et al Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262(12):1646–52. [PubMed: 2504944]
  89. Doty P, De Wit H Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav Pharmacol. 1995;6(4):386–94. [PubMed: 11224347]
  90. Drent ML, Zelissen PM, Koppeschaar HP, Nieuwenhuyzen Kruseman AC, Lutterman JA, van der Veen EA The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obesity Relat Metab Disord. 1995;19(5):299–304. [PubMed: 7647820]
  91. Duckert F, Johnsen J Behavioral use of disulfiram in the treatment of problem drinking. Int J Addict. 1987;22(5):445–54. [PubMed: 3596857]
  92. Edwards JDJ, Dill JE Alcoholism clinic in a military setting: a combined disulfiram and group therapy outpatient program. Mil Med. 1974;139(3):206–9. [PubMed: 4206169]
  93. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Archiv fur Psychiatrie Nervenkrankheiten. 1980;229(1):1–16. [PubMed: 6778456]
  94. Enghusen Poulsen H, Loft S, Andersen JR, Andersen M Disulfiram therapy -- adverse drug reactions and interactions. Acta Psychiatr Scand. 1992;86:59–66. [PubMed: 1471554]
  95. Epstein LH The direct effects of compliance on health outcome. Health Psychol. 1984;3(4):385–93. [PubMed: 6399250]
  96. Erickson CK, Chick J Consensus conference on the neuropharmacology of alcohol dependence and the role of pharmacotherapy in its treatment. Alcohol Alcohol. 1996;31(Suppl 1):5–11. [PubMed: 8924128]
  97. Estevez F, Parrillo S, Giusti M, Monti JM Single-dose ritanserin and alcohol in healthy volunteers: a placebo-controlled trial. Alcohol. 1995;12(6):541–5. [PubMed: 8590616]
  98. Evans SM, Griffiths RR, De Wit H Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacol (Berl) 1996;123(2):154–63. [PMC free article: PMC327140] [PubMed: 8741938]
  99. Ey SR Naltrexone hydrochloride use in the treatment of alcoholism. West J Med. 1996;165(4):–. [PMC free article: PMC1303756] [PubMed: 8987434]
  100. Fann WE, Karacan I, Pokorny AD, Williams RL Phenomenology and treatment of alcoholism. Jamaica, NY: Spectrum; 1980.
  101. Fantozzi R, Caramelli L, Ledda F, Moroni F, Masini E, Blandina P, Botti P, Perruzzi S, Zorn AM, Mannaioni PF Biological markers and therapeutic outcome in alcoholic disease: a twelve-year survey. Klinische Wochenschrift. 1987;65(1):27–33. [PubMed: 3560786]
  102. Farren CK, Dinan TG Platelet monoamine oxidase-B activity in alcoholics with lowered dopamine D2 receptor activity. Alcohol Alcohol. 1996;31(3):307–8. [PubMed: 8844038]
  103. Fawcett J Lithium carbonate in medicine and psychiatry. Adv Exp Med Biol. 1980;127:1–13. [PubMed: 6996456]
  104. Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbons RD A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44(3):248–56. [PubMed: 3103580]
  105. Fawcett J, Clark DC, Gibbons RD, Aagesen CA, Pisani VD, Tilken JM, Sellers D, Stutzman D Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45(12):494–9. [PubMed: 6389520]
  106. Ferguson FN A treatment program for Navaho alcoholics: results after four years. Q J Stud Alcohol. 1970;31(4):898–919. [PubMed: 5490825]
  107. Finley PR Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother. 1994;28(12):1359–69. [PubMed: 7696728]
  108. Finney JW, Monahan SC The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alcohol. 1996;57(3):229–43. [PubMed: 8709580]
  109. Food and Drug Administration Naltrexone approved for alcoholism treatment. Rockville, MD: Food and Drug Administration; 1995.
  110. Froehlich JC, Li TK Recent developments in alcoholism: opioid peptides. Recent Dev Alcohol. 1993;11:187–205. [PubMed: 7901877]
  111. Frost RE, Messiha FS Clinical uses of lithium salts. Brain Res Bull. 1983;11(2):219–31. [PubMed: 6414655]
  112. Fuller R Critical analysis of the efficacy and toxicity of the alcohol sensitizing drugs. In: Pharmacological treatments for alcoholism. New York: Methuen. 1984: p. 559–71.
  113. Fuller R Current status of alcoholism treatment outcome research. NIDA Res Monogr. 1989;95:85–91. [PubMed: 2701325]
  114. Fuller R, Roth H, Long S Compliance with disulfiram treatment of alcoholism. J Chron Dis. 1983;36(2):161–70. [PubMed: 6337171]
  115. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256(11):1449–55. [PubMed: 3528541]
  116. Fuller RK, Roth HP Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann Intern Med. 1979;90(6):901–4. [PubMed: 389121]
  117. Fuller RK, Williford WO Life-table analysis of abstinence in a study evaluating the efficacy of disulfiram. Alcohol Clin Exp Res. 1980;4(3):298–301. [PubMed: 6996515]
  118. Fuller RK, Williford WO, Lee KK, Derman R Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations. Control Clin Trials. 1984;5(3):263–73. [PubMed: 6386330]
  119. Fuller RW Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res. 1995;45:167–204. [PubMed: 8545537]
  120. Gaebel W, Pietzcker A Prospective study of course of illness in schizophrenia: Part III. Treatment and outcome. Schizophr Bull. 1987;13(2):307–16. [PubMed: 2887033]
  121. Gallant DM, Bishop MP, Faulkner MA, Simpson L, Cooper A, Lathrop D, Brisolara AM, Bossetta JR A comparative evaluation of compulsory (group therapy and-or antabuse) and voluntary treatment of the chronic alcoholic municipal court offender. Psychosomatics. 1968;9:306–10. [PubMed: 5725612]
  122. Geerlings PJ, Ansoms C, Van den Brink W Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. Eur Addict Res. 1997;3(3):129–37.
  123. George DT, Nutt DJ, Rawlings RR, Phillips MJ, Eckardt MJ, Potter WZ, Linnoila M Behavioral and endocrine responses to clomipramine in panic disorder patients with or without alcoholism. Biol Psychiatry. 1995;37(2):112–9. [PubMed: 7718674]
  124. George FR Pharmacotherapy in alcoholism treatment: integrating and understanding the use of serotonin reuptake inhibitors. Alcohol Alcohol Suppl. 1994;2:537–43. [PubMed: 8974380]
  125. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M Effects of fluoxetine and ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Cur Therapeu Res. 1992;52(2):291–5.
  126. Gerrein JR, Rosenberg CM, Manohar V Disulfiram maintenance in outpatient treatment of alcoholism. Arch Gen Psychiatry. 1973;28(6):798–802. [PubMed: 4707989]
  127. Ginzburg HM Naltrexone: its clinical utility. Rockville, MD: National Institute on Drug Abuse; 1984.
  128. Gluud C, Andersen I, Dietrichson O, Gluud B, Jacobsen A, Juhl E Gamma-glutamyltransferase, aspartate aminotransferase and alkaline phosphatase as markers of alcohol consumption in out-patient alcoholics. Eur J Clin Invest. 1981;11(3):171–6. [PubMed: 6115756]
  129. Goldman D Bromocriptine in the treatment of alcoholics. Nat Med. 1995;1(8):720–1. [PubMed: 7585161]
  130. Gonzalez ER Disulfiram doesn't always prevent drinking. JAMA. 1981;246(15):–. [PubMed: 7024575]
  131. Gordis E Alcohol research: promise for the decade. Rockville, MD: National Clearinghouse for Alcohol and Drug Information; 1991.
  132. Gorelick DA, Paredes A Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992;16(2):261–5. [PubMed: 1317133]
  133. Goyer PF, Brown GL, Minichiello MD, Major LF Mood-altering effects of disulfiram in alcoholics. J Stud Alcohol. 1984;45(3):209–13. [PubMed: 6748661]
  134. Grant BF Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. J Stud Alcohol. 1997;58(5):464–73. [PubMed: 9273910]
  135. Grant BF, Harford TC, Dawson DA, Chou P, Dufour M, Pickering R Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World. 1994;18(3):243–8.
  136. Grant BF, Harford TC, Hasin DS, Chou P, Pickering R DSM-III-R and the proposed DSM-IV alcohol use disorders, United States, 1988: a nosological comparison. Alcohol Clin Exp Res. 1992;16(2):215–21. [PubMed: 1590542]
  137. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B Naltrexone: a clinical perspective. J Clin Psychiatry. 1984;45(9 Pt. 2):25–8. [PubMed: 6469933]
  138. Guthrie SK Sertraline: a new specific serotonin reuptake blocker. DICP. 1991;25(9):952–61. [PubMed: 1949975]
  139. Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry. 1995;37(8):560–3. [PubMed: 7619981]
  140. Helander A, Carlsson S Carbohydrate-deficient transferrin and gamma-glutamyl transferase levels during disulfiram therapy. Alcohol Clin Exp Res. 1996;20(7):1202–5. [PubMed: 8904971]
  141. Higgins GA, Tomkins DM, Fletcher PJ, Sellers EM Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: studies using a drinkometer system. Neurosc Biobehav Rev. 1992;16:535–52. [PubMed: 1480350]
  142. Himmelhoch JM, Hill S, Steinberg B, May S Lithium, alcoholism and psychiatric diagnosis. J Psychiatr Treat Eval. 1983;5(1):83–8.
  143. Hirschowitz J, Hitzemann R, Kovasznay B, LaGrone H, Broggini G, Piscani K, Fittersak W, DeReuter J, Teitlebaum L, Dains K, et al Lithium antagonism of ethanol-induced intoxication: relationship to intracellular lithium levels. Psychiatry Res. 1989;29(1):55–63. [PubMed: 2505282]
  144. Hitzig P Combined serotonin and dopamine indirect agonists correct alcohol craving and alcohol-associated neuroses. J Subst Abuse Treat. 1994;11(5):489–90. [PubMed: 7869471]
  145. Hollister LE Clinical use of psychotherapeutic drugs: current status. Clin Pharmacol Ther. 1969;10(2):170–98. [PubMed: 4238455]
  146. Howard MO, Jenson JM Chemical aversion treatment of alcohol dependence. I. Validity of current criticisms. Int J Addict. 1990;25(10):1227–62. [PubMed: 2090625]
  147. Howard MO, McGuffin RW, Saxon AJ, Sloan KL, Walker RD Clinical issues related to the costs of alcoholism. Pharmacoeconomics. 1996;9(2):134–45. [PubMed: 10160092]
  148. Hughes JC, Cook CC The efficacy of disulfiram: a review of outcome studies. Addiction. 1997;92(4):381–95. [PubMed: 9177060]
  149. Hyytia JP, Sinclair D Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol Clin Exp Res. 1993;17:631–6. [PubMed: 8392818]
  150. Initial sensitivity to alcohol Proceedings of a workshop on alcohol intoxication, October 13-14, 1988; Keystone, CO. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1990.
  151. Ionescu-Pioggia M, Powell B, Samara B, Liskow B, Campbell J, Ascher J, Johnston A, Nickel J Bupropion in the treatment of primary alcoholism. In: Harris L, editor. Problems of drug dependence 1991: proceedings of the 53rd annual scientific meeting, Committee on Problems of Drug Dependence. Rockville, MD: National Institute on Drug Abuse; 1991. Chapter 6.
  152. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, O'Malley SS Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol. 1996;64(5):1044–53. [PubMed: 8916634]
  153. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation -- a VA cooperative study. Stat Med. 1996;15(13):1421–34. [PubMed: 8841652]
  154. Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996;11(2):109–17. [PubMed: 8803648]
  155. Janssen PA Addiction and the potential for therapeutic drug development. EXS. 1994;71:361–70. [PubMed: 8032167]
  156. Jellinek EM Alcoholism, a genus and some of its species. J Can Med Assoc. 1960;83:1341–5. [PMC free article: PMC1939063] [PubMed: 13789799]
  157. Jensen SB, Christoffersen CB, Noerregaard A Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study. Br J Addict Alcohol Other Drugs. 1977;72(4):325–30. [PubMed: 341937]
  158. Johnsen J, Morland J Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol Clin Exp Res. 1991;15(3):532–6. [PubMed: 1877740]
  159. Johnsen J, Morland J Depot preparations of disulfiram: experimental and clinical results. Acta Psychiatr Scand. 1992;369:27–30. [PubMed: 1471548]
  160. Johnsen J, Morland J [Disulfiram implants. Lack of pharmacological and clinical effects]. [Norwegian] Tidsskr Nor Laegeforen. 1990;110(10):1229–30. [PubMed: 2185582]
  161. Johnsen J, Stowell A, Bache-Wiig JE, Stensrud T, Ripel A, Morland J A double-blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation. Br J Addict. 1987;82(6):607–13. [PubMed: 3300757]
  162. Johnson BA, Campling GM, Griffiths P, Cowen PJ Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacol (Berl) 1993;112(1):142–4. [PMC free article: PMC327140] [PubMed: 7871004]
  163. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C Ritanserin in the treatment of alcohol dependence -- a multi-center clinical trial. Ritanserin Study Group. Psychopharmacol (Berl) 1996;128(2):206–15. [PMC free article: PMC327140] [PubMed: 8956382]
  164. Jovell AJ, Navarro-Rubio MD [Evaluation of the Scientific Evidence]. [Bar] Medicina Clinica. 1995;105:740–3. [PubMed: 8523956]
  165. Judd LL, Hubbard RB, Huey LY, Attewell PA, Janowsky DS, Takahashi KI Lithium carbonate and ethanol induced "highs" in normal subjects. Arch Gen Psychiatry. 1977;34(4):463–7. [PubMed: 322635]
  166. Judd LL, Huey LY Lithium antagonizes ethanol intoxication in alcoholics. Am J Psychiatry. 1984;141(12):1517–21. [PubMed: 6439054]
  167. Julius DA, Renault P Narcotic antagonists - naltrexone: progress report. Rockville, MD: National Institute on Drug Abuse; 1976.
  168. Kabel DI, Petty F A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996;20(4):780–4. [PubMed: 8800399]
  169. Kadden RM, Litt MD, Cooney NL Matching alcoholics to coping skills or interactional therapies. Role of intervening variables. Ann N Y Acad Sci. 1994;708:218–29. [PubMed: 8154683]
  170. Kalant H Pharmacological treatment of dependence on alcohol and other drugs: overview. Approaches to treatment of substance abuse. Geneva, Switzerland: World Health Organization. 1993:p. 75–102.
  171. Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ A population-based twin study of alcoholism in women. JAMA. 1992;268(14):1877–82. [PubMed: 1404711]
  172. King AC, Volpicelli JR, Frazer A, O'Brien CP Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacol (Berl) 1997;129(1):15–22. [PMC free article: PMC327140] [PubMed: 9122358]
  173. Kiorboe E Phenytoin intoxication during treatment with Antabuse (disulfiram) Epilepsia. 1966;7(3):246–9. [PubMed: 5332920]
  174. Kleber HD, Anton RF, Chick J, Croop R, O'Brien CP Clinical applications of new alcoholism studies. Am J Addict. 1996;5:S38–44.
  175. Kline NS, Wren JC, Cooper TB, Varga E, Canal O Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci. 1974;268(1):15–22. [PubMed: 4606532]
  176. Kline SA, Kingstone E Disulfiram implants: the right treatment but the wrong drug? Can Med Assoc J. 1977;116(12):1382–3. [PMC free article: PMC1879293] [PubMed: 861898]
  177. Knox PC Reducing craving and recidivism with naltrexone in inpatient alcoholism treatment, a clinical study. Dissertation Abstr Int. 1997;57(10):–.
  178. Knox WJ Four-year follow-up of veterans treated on a small alcoholism treatment ward. Q J Stud Alcohol. 1972;33(1):105–10. [PubMed: 4551019]
  179. Kofoed L, Kania J, Walsh T, Atkinson RM Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry. 1986;143(7):867–72. [PubMed: 3087222]
  180. Kofoed LL Chemical monitoring of disulfiram compliance: a study of alcoholic outpatients. Alcohol Clin Exp Res. 1987;11(5):481–5. [PubMed: 3314565]
  181. Koob GF, Bloom FE Cellular and molecular mechanisms of drug dependence. Science. 1988;242(4879):715–23. [PubMed: 2903550]
  182. Koufen H [Indications for and side effects of lithium therapy. Present status]. [German] Medizinische Welt. 1979;30(37):1339–42. [PubMed: 388145]
  183. Kranzler HR Evaluation and treatment of anxiety symptoms and disorders in alcoholics. J Clin Psychiatry. 1996;57:15–21. [PubMed: 8690692]
  184. Kranzler HR Treatment of alcohol dependence. Liver Transpl Surg. 1997;3(3):311–21. [PubMed: 9346757]
  185. Kranzler HR, Anton RF Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism. J Consult Clin Psychol. 1994;62(6):1116–26. [PubMed: 7860810]
  186. Kranzler HR, Burleson JA, Brown J, Babor TF Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20(9):1534–41. [PubMed: 8986200]
  187. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry. 1994;51(9):720–31. [PubMed: 8080349]
  188. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152(3):391–7. [PubMed: 7864265]
  189. Kranzler HR, Del Boca F, Korner P, Brown J Adverse effects limit the usefulness of fluvoxamine for the treatment of alcoholism. J Subst Abuse Treat. 1993;10(3):283–7. [PubMed: 8315702]
  190. Kranzler HR, Dolinsky Z, Kaplan RF Giving ethanol to alcoholics in a research setting: its effect on compliance with disulfiram treatment. Br J Addict. 1990;85(1):119–23. [PubMed: 2310844]
  191. Kranzler HR, Meyer RE An open trial of buspirone in alcoholics. J Clin Psychopharmacol. 1989;9(5):379–80. [PubMed: 2677064]
  192. Kranzler HR, Tennen H, Penta C, Bohn MJ Targeted naltrexone treatment of early problem drinkers. Addict Behav Int J. 1997;22(3):431–6. [PubMed: 9183513]
  193. Krasner N, Moore MR, Goldberg A, Booth JC, Frame AH, McLaren AD A trial of fenfluramine in the treatment of the chronic alcoholic patient. Br J Psychiatry. 1976;128:346–53. [PubMed: 4188]
  194. Kresyn VI, Aryaev VL, Kostev FI Litonit: evaluation of clinical effectiveness. Alcohol Alcohol. 1993;28(3):333–7. [PubMed: 8352844]
  195. Kristenson H How to get the best out of Antabuse. Alcohol Alcohol. 1995;30(6):775–83. [PubMed: 8679019]
  196. Kulik FAW Detoxification of alcoholics with drugs: Perspectives in treatment and research. Alcohol Health Res World. 1981;6(1):50–4.
  197. Ladewig D, Knecht T, Leher P, Fendl A [Acamprosate - a stabilizing factor in long-term withdrawal of alcoholic patients]. [German] Ther Umsch. 1993;50(3):182–8. [PubMed: 8475472]
  198. Landry M Overview of addiction treatment effectiveness. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1995.
  199. Larson EW, Olincy A, Rummans TA, Morse RM Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16(1):125–30. [PubMed: 1558293]
  200. Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Ritchie T, Noble EP Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med. 1995;1(4):337–41. [PubMed: 7585063]
  201. Lejoyeux M Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol. 1996;31(suppl 1):69–75. [PubMed: 8737004]
  202. Lejoyeux M, Ades J Evaluation of lithium treatment in alcoholism. Alcohol Alcohol. 1993;28(3):273–9. [PubMed: 8352838]
  203. LeMarquand D, Pihl RO, Benkelfat C Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychiatry. 1994;36(6):395–421. [PubMed: 7803601]
  204. Levy MS, Livingstone BL, Collins DM A clinical comparison of disulfiram and calcium carbimide. Am J Psychiatry. 1967;123(8):1018–22. [PubMed: 5334883]
  205. Lewis DC The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone. Am J Drug Alcohol Abuse. 1975;2(3-4):403–15. [PubMed: 1227300]
  206. Lewis MJ, Bland RC, Baile W Disulfiram implantation for alcoholism. Can Psychiatr Assoc J. 1975;20(4):283–6. [PubMed: 1182640]
  207. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Boismare F, Hillemand B Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1(8436):1014–6. [PubMed: 2859465]
  208. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F, et al Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25(6):613–22. [PubMed: 2085344]
  209. Lieber CS Biological approach to alcoholism. NIAAA research monograph no. 11. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1983.
  210. Ling W, Weiss DG, Charuvastra VC, O'Brien CP Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration cooperative study. Arch Gen Psychiatry. 1983;40(8):851–4. [PubMed: 6347118]
  211. Linnoila M, Stapleton JM, George DT, Lane E, Eckardt MJ Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol. 1993;13(3):175–80. [PubMed: 8354733]
  212. Liskow B, Nickel E, Tunley N, Powell BJ, Penick EC Alcoholics' attitudes toward and experiences with disulfiram. Am J Drug Alcohol Abuse. 1990;16(1-2):147–60. [PubMed: 2330935]
  213. Litman GK, Topham A Outcome studies on techniques in alcoholism treatment. Recent Dev Alcohol. 1983;1:167–94. [PubMed: 6390549]
  214. Litten RZ International update: new findings on promising medications. Alcohol Clin Exp Res. 1996;20(8 Suppl):216A–8A. [PubMed: 8947268]
  215. Litten RZ, Allen JP Advances in development of medications for alcoholism treatment. Psychopharmacology. 1998;139(1-2):20–33. [PubMed: 9768539]
  216. Litten RZ, Allen J, Fertig J Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin Exp Res. 1996;20(5):859–76. [PubMed: 8865961]
  217. Littleton J Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90(9):1179–88. [PubMed: 7580816]
  218. Lohr KN Grading articles and evidence: issues and options. Final report submitted to the Agency for Health Care Policy and Research (contract 290-97-0011). Research Triangle Park, NC: Research Triangle Institute; May 1998.
  219. Lovinger DM Interactions between ethanol and agents that act on the NMDA-type glutamate receptor. Alcohol Clin Exp Res. 1996;20(8 Suppl):187A–91A. [PubMed: 8947262]
  220. Ludwig A, Levine J, Stark L, Lazar R A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59–69. [PubMed: 5798383]
  221. Ludwig AM On and off the wagon. Reasons for drinking and abstaining by alcoholics. Q J Stud Alcohol. 1972;33(1):91–6. [PubMed: 5059562]
  222. Lundwall L, Baekeland F Disulfiram treatment of alcoholism . J Nerv Ment Dis. 1971;153(6):381–94. [PubMed: 4941777]
  223. Major LF, Murphy DL, Lershon ES, Brown GL The role of plasma amine oxidase, platelet monoamine oxidase, and red cell catechol-O-methyl transferase in severe behavioral reactions to disulfiram. Am J Psychiatry. 1979;136(5):679–84. [PubMed: 434246]
  224. Majumdar SK Chlormethiazole: Current status in the treatment of the acute ethanol withdrawal syndrome. Drug Alcohol Depend. 1991;27(3):201–7. [PubMed: 1884662]
  225. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992;16(6):1007–13. [PubMed: 1335217]
  226. Malec E, Malec T, Gagne MA, Dongier M Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res. 1996;20(2):307–12. [PubMed: 8730222]
  227. Malec TS, Dobkin PL, Dongier M, Ghadirian AM, Kealey S Clinical trial of the combination of L-tryptophan and lithium in the treatment of chronic alcoholism. Lithium. 1994;5(1):23–7.
  228. Malec TS, Malec EA, Dongier M Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res. 1996;20(5):853–8. [PubMed: 8865960]
  229. Mason BJ Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res. 1996;20:10–6A. [PubMed: 8904989]
  230. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994;18(5):1162–7. [PubMed: 7847600]
  231. Mayo-Smith MF Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144–51. [PubMed: 9214531]
  232. McBride WJ, Guan X-M, Chernet E, Lumeng L, Li T-K Regional serotonin 1A receptors in the CNS of alcohol-preferring and -nonpreferring rats. Pharmacol Biochem Behav. 1994;49(1):7–12. [PubMed: 7816892]
  233. McCrady BS, Langenbucher JW Alcohol treatment and health care system reform. Arch Gen Psychiatry. 1996;53:737–46. [PubMed: 8694687]
  234. McDonald AM, Dyer AR, Liu K, Stamler R, Gosch FC, Grimm R, Berman R, Stamler J Sodium, lithium-countertransport and blood pressure control by nutritional intervention in 'mild' hypertension. J Hypertens. 1988;6(4):283–91. [PubMed: 2454254]
  235. McGinnis JM, Foege WH Actual causes of death in the United States. JAMA. 1993;270(18):2207–12. [PubMed: 8411605]
  236. McLachlan JF, Stein RL Evaluation of a day clinic for alcoholics. J Stud Alcohol. 1982;43(3):261–72. [PubMed: 7120997]
  237. McMillan TM Lithium and the treatment of alcoholism: a critical review. Br J Addict. 1981;76(3):245–58. [PubMed: 6791674]
  238. McMillen BA Reviews and comments on alcohol research. Alcohol. 1994;11(1):61–2.
  239. McNichol RW, Sowell JM, Logsdon SA, Delgado MH, McNichol J Disulfiram: a guide to clinical use in alcoholism treatment. Am Fam Physician. 1991;44(2):481–4. [PubMed: 1858605]
  240. Meert TF Ritanserin and alcohol abuse and dependence. Alcohol Alcohol Suppl. 1994;2:523–30. [PubMed: 8974378]
  241. Merry J, Reynolds CM, Bailey J, Coppen A Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet. 1976;1(7984):481–2. [PubMed: 74457]
  242. Meszaros K, Willinger U, Fischer G, Schonbeck G, Aschauer HN The tridimensional personality model: influencing variables in a sample of detoxified alcohol dependents. European Fluvoxamine in Alcoholism Study Group. Compr Psychiatry. 1996;37(2):109–14. [PubMed: 8654059]
  243. Meyer RE Conditioning phenomena and the problem of relapse in opioid addicts and alcoholics. NIDA Res Monogr. 1988;84:161–79. [PubMed: 3147381]
  244. Meza E, Kranzler HR Closing the gap between alcoholism research and practice: The case for pharmacotherapy. Psychiatr Serv. 1996;47(9):917–20. [PubMed: 8875651]
  245. Miller NS Pharmacotherapy in alcoholism. J Addict Dis. 1995;14(1):23–46. [PubMed: 7632745]
  246. Miller WR, Hester RK The effectiveness of alcoholism treatment methods: what research reveals.In: Miller WR, Heather N, editors. Treating addictive behaviors: processes of change. New York: Plenum Press; 1986.
  247. Moore , Libert C Acamprosate, citalopram, and alcoholism. Lancet. 1991;337(8751):–. [PubMed: 1673769]
  248. Morley JA, Finney JW, Monahan SC, Floyd AS Alcoholism treatment outcome studies, 1980-1992: methodological characteristics and quality. Addict Behav. 1996;21(4):429–43. [PubMed: 8830902]
  249. Morse RM, Flavin DK The definition of alcoholism. Joint Committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism. JAMA. 1992;268(8):1012–4. [PubMed: 1501306]
  250. Mozzato MG, Semplicini A, Zamboni S, Urbani V, Marzola M, Mazzucato L, Ambrosio GB, Pessina AC [Erythrocyte Li/Na countertransport and correlated variables in a randomized sample of population]. [Italian] Cardiologia. 1989;34(4):347–51. [PubMed: 2758440]
  251. Murthy KK Psychosis during disulfiram therapy for alcoholism. J Indian Med Assoc. 1997;95(3):80–1. [PubMed: 9212576]
  252. Myers WC, Donahue JE, Goldstein MR Disulfiram for alcohol use disorders in adolescents. J Am Acad Child Adolesc Psychiatry. 1994;33(4):484–9. [PubMed: 8005901]
  253. Nagel K, Adler LE, Bell J, Nagamoto HT, Freedman R Lithium carbonate and mood disorder in recently detoxified alcoholics: a double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res. 1991;15(6):978–81. [PubMed: 1789394]
  254. Nalpas B, Dabadie H, Parot P, Paccalin J [Acamprosate. From pharmacology to therapeutics]. [French] Encephale. 1990;16(3):175–9. [PubMed: 2167200]
  255. Naranjo CA, Bazoon M, Turksen IB Using fuzzy logic modeling to predict response to pharmacotherapy in alcohol dependence. Problems of drug dependence 1996: proceedings of the 58th annual scientific meeting. NIDA Res Monogr. 1997;174:–.
  256. Naranjo CA, Bremner KE Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption. Alcohol Alcohol. 1993;2:221–9. [PubMed: 7748304]
  257. Naranjo CA, Bremner KE Serotonin-altering medications and desire, consumption and effects of alcohol-treatment implications. EXS. 1994;71:209–19. [PubMed: 8032152]
  258. Naranjo CA, Bremner KE, Lanctot KL Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction. 1995;90(1):87–99. [PubMed: 7888983]
  259. Naranjo CA, Bremner KE, Poulos CX Research strategies to assess pharmacotherapies for alcoholism. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(4):543–59. [PubMed: 8843484]
  260. Naranjo CA, Cappell H, Sellers EM Pharmacological control of alcohol consumption: tactics for the identification and testing of new drugs. Addict Behav. 1981;6(3):261–9. [PubMed: 7027758]
  261. Naranjo CA, Dongier M, Bremner KE Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction. 1997;92(8):969–78. [PubMed: 9376779]
  262. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990;47(4):490–8. [PubMed: 2328557]
  263. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992;51(6):729–39. [PubMed: 1535302]
  264. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL Fluoxetine attenuates alcohol intake and desire to drink. Int Clin Psychopharmacol. 1994;9(3):163–72. [PubMed: 7814825]
  265. Naranjo CA, Poulos CX, Lanctot KL, Bremner KE, Kwok M, Umana M Ritanserin, a central 5-HT2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction. 1995;90(7):893–905. [PubMed: 7663312]
  266. Naranjo CA, Sellers EM Research advances in new psychopharmacological treatments for alcoholism: proceedings of the symposium.International Congress series 664: October 4-5, 1984;Toronto. New York: Elsevier; 1985.
  267. Naranjo CA, Sellers EM Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers. Recent Dev Alcohol. 1989;7:255–66. [PubMed: 2522667]
  268. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984;35(3):374–81. [PubMed: 6230195]
  269. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987;41(3):266–74. [PubMed: 3469057]
  270. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther. 1989;46(3):301–9. [PubMed: 2673621]
  271. National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) The economic costs of alcohol and drug abuse in the United States, 1992. Bethesda, MD: National Institutes of Health, 1998.
  272. New hope for alcoholics Alcohol Drug Rev 1993.
  273. Nieper HA The clinical applications of lithium orotate. A two year study. Agressologie. 1973;14(6):407–11. [PubMed: 4607169]
  274. Ninth special report to the U.S. Congress on alcohol and health Chapter 1: Epidemiology of alcohol use and alcohol-related consequences. Washington: Public Health Service, June 1997.
  275. Nunes EV, McGrath PJ, Quitkin FM, Stewart JP, Harrison W, Tricamo E, Ocepek-Welikson K Imipramine treatment of alcoholism with comorbid depression. Am J Psychiatry. 1993;150(6):963–5. [PubMed: 8494079]
  276. Nuotto E, Mattila M Failure of amantadine and bromocriptine to counteract alcoholic inebriation in man. Acta Pharmacol Toxicol. 1984;55(3):168–73. [PubMed: 6507109]
  277. O'Brien CP Treatment of alcoholism as a chronic disorder. Alcohol. 1994;11(6):433–7. [PubMed: 7865139]
  278. O'Brien CP Treatment of alcoholism as a chronic disorder. EXS. 1994;71:349–59. [PubMed: 8032166]
  279. O'Brien CP, McLellan AT Addiction medicine. JAMA. 1997;277(23):1840–1. [PubMed: 9185790]
  280. O'Brien CP, Volpicelli LA, Volpicelli JR Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13(1):35–9. [PubMed: 8837932]
  281. O'Carroll RE, Moffoot AP, Ebmeier KP, Goodwin GM Effects of fluvoxamine treatment on cognitive functioning in the alcoholic Korsakoff syndrome. Psychopharmacol (Berl) 1994;116(1):85–8. [PMC free article: PMC327140] [PubMed: 7862935]
  282. O'Connor PG, Schottenfeld RS Patients with alcohol problems. N Engl J Med. 1998;338(9):592–602. [PubMed: 9475768]
  283. O'Farrell TJ, Allen JP, Litten RZ Disulfiram (Antabuse) contracts in treatment of alcoholism. NIDA Res Monogr. 1995;150:65–91. [PubMed: 8742773]
  284. O'Malley SS Current strategies for the treatment of alcohol dependence in the United States. Drug Alcohol Depend. 1995;39:S3–S7. [PubMed: 8565795]
  285. O'Malley SS Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. J Clin Psychiatry. 1995;56(Suppl 7):30–8. [PubMed: 7673103]
  286. O'Malley SS Strategies to maximize the efficacy of naltrexone for alcohol dependence. NIDA Res Monogr. 1995;150:53–64. [PubMed: 8742772]
  287. O'Malley SS Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol. 1996;31:77–81. [PubMed: 8737005]
  288. O'Malley SS, Carroll KM Psychotherapeutic considerations in pharmacological trials. Alcohol Clin Exp Res. 1996;20(7):17A–22A. [PubMed: 8904990]
  289. O'Malley SS, Croop RS, Wroblewski JM, Labriola DF, Volpicelli JR Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr Ann. 1995;25(11):681–8.
  290. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53(3):217–24. [PubMed: 8611058]
  291. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7. [PubMed: 1444726]
  292. O'Malley SS, Jaffe A, Chang G, Witte G, Schottenfeld RS, Rounsaville BJ Naltrexone in the treatment of alcohol dependence: preliminary findings.Novel pharmacological interventions for alcoholism, June 16-17, 1990;Toronto. New York: Springer-Verlag; 1992.
  293. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ Experience of a "slip" among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996;153(2):281–3. [PubMed: 8561215]
  294. O'Mara NB, Wesley LC Naltrexone in the treatment of alcohol dependence. Ann Pharmacother. 1994;28(2):210–1. [PubMed: 8173139]
  295. O'Sullivan K Depression and its treatment in alcoholics: a review. Can J Psychiatry. 1984;29(5):379–84. [PubMed: 6434175]
  296. Obholzer AM A follow-up study of nineteen alcoholic patients treated by means of tetraethyl-thiuram disulfide (antabuse) implants. Br J Addict Alcohol Other Drugs. 1974;69(1):19–23. [PubMed: 4141260]
  297. Ojehagen A, Berglund M To keep the alcoholic in out-patient treatment. A differentiated approach through treatment contracts. Acta Psychiatr Scand. 1986;73(1):68–75. [PubMed: 3962705]
  298. Ojehagen A, Skjaerris A, Berglund M Long-term use of aversive drugs in outpatient alcoholism treatment. Acta Psychiatr Scand. 1991;84(2):185–90. [PubMed: 1950615]
  299. Olbrich R, Watzl H, Volter M, Siedow H Lithium in the treatment of chronic alcoholic patients with brain damage: a controlled study. [German] Nervenarzt. 1991;62(3):182–6. [PubMed: 2052117]
  300. Oslin D, Liberto JG, O'Brien J, Krois S Tolerability of naltrexone in treating older, alcohol-dependent patients. Am J Addict. 1997;6(3):266–270. [PubMed: 9256993]
  301. Overstreet DH Alternatives to naltrexone in animal models. Alcohol Clin Exp Res. 1996;20(8 Suppl):231A–5A. [PubMed: 8947271]
  302. Paille F, Gillet C Apport de l'acamprosate dans l'aide au maintien de l'abstinence chez l'alcoolo-dependant (Acamprosate as an aid in maintaining abstinence in alcoholics) Alcoologie. 1996;18(4):345–51.
  303. Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239–47. [PubMed: 7662044]
  304. Palliyath S, Schwartz BD Disulfiram neuropathy: electrophysiological study. Electromyogr Clin Neurophysiol. 1988;28(5):245–7. [PubMed: 2847909]
  305. Pasatu P, Winter E [On the stationary treatment of alcoholism and its results in catamnestic regard. 2. Analysis of treatment of alcoholics (period 1963-1964)]. [German] Psychiatrie, Neurologie Medizinische Psychologie. 1965;17(12):458–62. [PubMed: 5874952]
  306. Peachey JE, Zilm DH, Cappell H "Burning off the antabuse": fact or fiction? Lancet. 1981;1(8226):943–4. [PubMed: 6112345]
  307. Peachey JE, Zilm DH, Robinson GM, Jacob M, Cappell H A placebo-controlled double-blind comparative clinical study of the disulfiram- and calcium carbimide-acetaldehyde mediated ethanol reactions in social drinkers. Alcohol Clin Exp Res. 1983;7(2):180–7. [PubMed: 6346921]
  308. Peck CC, Pond SM, Becker CE, Lee K An evaluation of the effects of lithium in the treatment of chronic alcoholism. II. Assessment of the two-period crossover design. Alcohol Clin Exp Res. 1981;5(2):252–5. [PubMed: 7018306]
  309. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73–7. [PubMed: 9328500]
  310. Penick EC, Powell BJ, Campbell J, Liskow BI, Nickel EJ, Dale TM, Thomas HM, Laster LJ, Noble E Pharmacological treatment for antisocial personality disorder alcoholics: a preliminary study. Alcohol Clin Exp Res. 1996;20(3):477–84. [PubMed: 8727240]
  311. Perier C, Janin J, Pierre-Louis S, Frey J Reversal of changes in lipoprotein A and lipoprotein B cholesterol during and for a year after a detoxication treatment program in chronic alcoholism. Clin Chem. 1983;29(5):874–5. [PubMed: 6839471]
  312. Phillips M Persistent sensitivity to ethanol following a single dose of parenteral sustained-release disulfiram. Adv Alcohol Subst Abuse. 1987;7(1):51–61. [PubMed: 3442274]
  313. Phillips M, Greenberg J Dose-ranging study of depot disulfiram in alcohol abusers. Alcohol Clin Exp Res. 1992;16(5):964–7. [PubMed: 1443436]
  314. Pisani VD, Fawcett J, Clark DC, McGuire M The relative contributions of medication adherence and AA meeting attendance to abstinent outcome for chronic alcoholics. J Stud Alcohol. 1993;54(1):115–9. [PubMed: 8394956]
  315. Poldrugo F Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537–46. [PubMed: 9519495]
  316. Pond SM, Becker CE, Vandervoort R, Phillips M, Bowler RM, Peck CC An evaluation of the effects of lithium in the treatment of chronic alcoholism. I. Clinical results. Alcohol Clin Exp Res. 1981;5(2):247–51. [PubMed: 7018305]
  317. Poser W, Ehrenreich H [Naltrexone -- prevention of recurrence in narcotic dependence and in alcoholism]. [German] Internist (Berl) 1996;37(10):1061–7. [PMC free article: PMC152703] [PubMed: 9019453]
  318. Powell BJ, Campbell JL, Landon JF, et al A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res. 1995;19(2):462–8. [PubMed: 7625583]
  319. Powell BJ, Penick EC, Liskow BI, Rice AS, McKnelly W Lithium compliance in alcoholic males: a six-month followup study. Addict Behav. 1986;11(2):135–40. [PubMed: 3090864]
  320. Powell BJ, Penick EC, Read MR, Ludwig AM Comparison of three outpatient treatment interventions: a twelve-month follow-up of men alcoholics. J Stud Alcohol. 1985;46(4):309–12. [PubMed: 2993750]
  321. Prigatano GP Neuropsychological functioning of recidivist alcoholics treated with disulfiram: a follow-up report. Int J Addict. 1980;15(2):287–94. [PubMed: 7399760]
  322. Ramirez G, Ables MF, Butcher DE, Morris AD Evaluation of the hypothalamic-hypophysial, thyroid, and gonadal axes before and after disulfiram administration in patients with chronic alcoholism. South Med J. 1988;81(11):1407–11. [PubMed: 3055325]
  323. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. JAMA. 1990;264(19):2511–8. [PubMed: 2232018]
  324. Reynolds CM, Merry J, Bailey J, et al A double-blind trial of lithium carbonate in alcoholism. In: Johnson FN, Johnson F, editors. Lithium in medical practice. Lancaster, Eng: MTP Press. 1978: p. 53–60.
  325. Reynolds CM, Merry J, Coppen A Prophylactic treatment of alcoholism by lithium carbonate: an initial report. Alcohol Clin Exp Res. 1977;1(2):109–11. [PubMed: 337829]
  326. Rezvani AH, Pucilowski O, Grady DR, Janowsky D, O'Brien RA Reduction of spontaneous alcohol drinking and physical withdrawal by levemopamil, a novel Ca2 channel antagonist, in rats. Pharmacol Biochem Behav. 1993;46(2):365–71. [PubMed: 8265691]
  327. Rice DP The economic cost of alcohol and alcohol dependence: 1990. Alcohol Health Res World. 1993;17(1):10–11.
  328. Rice DP, Kelman S, Miller LS, Dunmeyer S The economic costs of alcohol and drug abuse and mental illness: 1985. Washington: US Government Printing Office; 1986.
  329. Ritson B Involvement in treatment and its relation to outcome amongst alcoholics. Br J Addict Alcohol Other Drugs. 1969;64(1):23–9. [PubMed: 5253627]
  330. Rock NL, Donley PJ Treatment program for military personnel with alcohol problems. Part II. The program. Int J Addict. 1975;10(3):467–80. [PubMed: 1176225]
  331. Rommelspacher H, Schmidt LG, Helmchen H Pathobiochemistry and pharmacotherapy of alcohol withdrawal delirium. Nervenarzt. 1991;62(11):649–57. [PubMed: 1685217]
  332. Rosenbaum AH, Niven RG, Hanson NP, Swanson DW Tardive dyskinesia: relationship with a primary affective disorder. Dis Nerv System. 1977;38(6):423–7. [PubMed: 16734]
  333. Rosenberg CM The use of marihuana in the treatment of alcoholism, p.173-82. Cohen S, editor. The therapeutic potential of marihuana. New York: Plenum Medical Books; 1976.
  334. Rothman, KJ Modern epidemiology. Boston: Little, Brown; 1986.
  335. Rothman RB Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series. J Subst Abuse Treat. 1995;12(6):449–53. [PubMed: 8749729]
  336. Rothstein E, Clancy DD Toxicity of disulfiram combined with metronidazole. New Engl J Med. 1969;280(18):1006–7. [PubMed: 4888076]
  337. Rothstein E, Clancy DD Combined use of disulfiram and metronidazole in treatment of alcoholism. Q J Stud Alcohol. 1970;31(2):446–7. [PubMed: 4921397]
  338. Roussaux JP, Hers D, Ferauge M [Does acamprosate diminish the appetite for alcohol in weaned alcoholics?]. [French] J Pharm Belg. 1996;51(2):65–8. [PubMed: 8786520]
  339. Rowe JB, Sullivan PF, Mulder RT, Joyce PR The effect of a history of conduct disorder in adult major depression. J Affect Disord. 1996;37(1):51–63. [PubMed: 8682978]
  340. Rush CR, Griffiths RR Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp Clin Psychopharmacol. 1997;5(1):28–38. [PubMed: 9234037]
  341. Saenz ED, Chen SW What is the role of naltrexone (ReVia) in treating alcohol dependence? California Pharmacist. 1995;42:26–7.
  342. Salvato FR, Mason BJ Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res. 1994;18(5):1187–9. [PubMed: 7847604]
  343. Sartori HE Lithium orotate in the treatment of alcoholism and related conditions. Alcohol. 1986;3(2):97–100. [PubMed: 3718672]
  344. Sass H, Soyka M, Mann K, Zieglgansberger W Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53(8):673–80. [PubMed: 8694680]
  345. Schou M Lithium in the treatment of other psychiatric and nonpsychiatric disorders. Arch Gen Psychiatry. 1979;36:865–9. [PubMed: 378163]
  346. Schuckit MA A one-year follow-up of men alcoholics given disulfiram. J Stud Alcohol. 1985;46(3):191–5. [PubMed: 4010293]
  347. Schuckit MA Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol. 1996;64(4):669–76. [PubMed: 8803356]
  348. Schuckit MA Acamprosate: a new drug for the treatment of alcoholism. Drug Abuse Alcohol News. 1997;26(2)
  349. Schuckit MA, Tipp JE, Smith TL, Bucholz KK Periods of abstinence following the onset of alcohol dependence in 1,853 men and women. J Studies Alcohol. 1997;58:581–9. [PubMed: 9391917]
  350. Sellers EM, Amit Z, Deitrich RA, Martin PR, Naranjo CA Panel discussion: research priorities and methodological issues on basic and human research. Research advances in new psychopharmacological treatments for alcoholism, October 4-5, 1984;Toronto. New York: Elsevier. 1985: p. 275–82.
  351. Sellers EM, Busto U, Kaplan HL Pharmacokinetic and pharmacodynamic drug interaction: implications for abuse liability testing. Testing for abuse liability of drugs in humans, November 5-6. 1988;Princeton, NJ. p:287–306.
  352. Sellers EM, Cooper SD, Zilm DH, Shanks C Lithium treatment during alcoholic withdrawal. Clin Pharmacol Ther. 1976;20(2):199–206. [PubMed: 181193]
  353. Sellers EM, Higgins GA, Tompkins DM, Romach MK Serotonin and alcohol drinking. NIDA Res Monogr. 1992;119:141–5. [PubMed: 1435969]
  354. Sellers EM, Kadlec KE, Kaplan HL, Naranjo CA Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption. J Stud Alcohol. 1988;49(6):567–70. [PubMed: 2976866]
  355. Sellers EM, Naranjo CA, Kadlec K Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol. 1987;7(6):417–20. [PubMed: 2963034]
  356. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18(4):879–85. [PubMed: 7978099]
  357. Sereny G, Fryatt M A follow-up evaluation of the treatment of chronic alcoholics. Can Med Assoc J. 1966;94(1):8–12. [PMC free article: PMC1935154] [PubMed: 5901400]
  358. Sereny G, Sharma V, Holt J, Gordis E Mandatory supervised antabuse therapy in an outpatient alcoholism program: a pilot study. Alcohol Clin Exp Res. 1986;10(3):290–2. [PubMed: 3526952]
  359. Shergill SS Disulfiram implantation. Psychiatr Bull. 1996;20(10):–.
  360. Sinclair JD The feasibility of effective psychopharmacological treatments for alcoholism [see comments] Br J Addict. 1987;82(11):1213–23. [PubMed: 2892522]
  361. Slywka S, Hart LL Fluoxetine in alcoholism. Ann Pharmacother. 1993;27(9):1066–7. [PubMed: 8219441]
  362. Smith JW Rehabilitation for alcoholics. Postgrad Med. 1978;64(6):143–8,52. [PubMed: 740566]
  363. Snyder S, Karacan I, Salis PJ Effects of disulfiram on the sleep of chronic alcoholics. Curr Alcohol. 1981;8:159–66. [PubMed: 6282542]
  364. Snyder S, Keeler M Acute effects of disulfiram on anxiety levels of chronic alcoholics. Int Pharmacopsychiatry. 1981;16(1):49–56. [PubMed: 7028657]
  365. Soyka M Efficacy of acamprostate in the relapse prevention of alcohol dependence. Results of clinical trials and therapeutical prospects. Nervenheilkunde. 1995;14(214):83–6.
  366. Soyka M Pharmacotherapy and psychotherapy for the treatment of alcoholism in Germany. Drug Alcohol Depend. 1995;39:S9–13. [PubMed: 8565796]
  367. Soyka M Pharmacotherapy of alcoholism. Drugs for preventing relapse. Munchener Med Wochen. 1995;137(43):3–740.
  368. Soyka M, Hippius H Acamprosate in the treatment of alcoholics. Psychopharm. 1996;3(3):98–102.
  369. Soyka M, Kotter G, Preuss U, Schutz C [Pharmacotherapy of alcoholism]. [German] Med Monats Fur Pharm. 1996;19(12):359–64.
  370. Soyka M, Sass H Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism - preliminary data. Alcohol Alcohol. 1994;Suppl 2:531–6. [PubMed: 8974379]
  371. Spanagel R, Zieglgansberger W Anti-craving components for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18:54–9. [PubMed: 9090311]
  372. Squire LR, Judd LL, Janowsky DS, Huey LY Effects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry. 1980;137(9):1042–6. [PubMed: 7425151]
  373. Stimmel B Pharmacological issues in alcohol and substance abuse.New York: Haworth Press; 1988.
  374. Sullivan JT, Naranjo CA, Sellers EM Compliance among heavy alcohol users in clinical drug trials. J Subst Abuse. 1988-1989;1(2):183–94. [PubMed: 2980999]
  375. Swift RM Effect of naltrexone on human alcohol consumption. J Clin Psychiatry. 1995;56(Suppl 7):24–9. [PubMed: 7673102]
  376. Swift RM, Davidson D, Whelihan W, Kuznetsov O Ondansetron alters human alcohol intoxication. Biol Psychiatry. 1996;40(6):514–21. [PubMed: 8879472]
  377. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151(10):1463–7. [PubMed: 8092339]
  378. Sytinsky IA, Gurevitch ZP Modern methods in treatment of chronic alcoholism: a review of the Soviet literature. Addict Behav. 1976;1(4):269–79. [PubMed: 793322]
  379. Thevos AK, Brown JM, Malcolm R, Randall CL Alcohol treatment: measurement of effectiveness by global outcome. Soc Work Health Care. 1996;23(3):57–71. [PubMed: 8865515]
  380. Thomas R Fluvoxamine and alcoholism. Int Clin Psychopharmacol. 1991;6(Suppl 3):85–90. [PubMed: 1806637]
  381. Thomson AD, Ryle PR, World MJ, Shaw G Treatment and prevention of alcohol related tissue damage: currently available drug treatments and their future. In Pharmacological treatments for alcoholism. New York: Methuen. 1984. pp. 373–404. [PMC free article: PMC331391] [PubMed: 14757676]
  382. Tiihonen J, Ryynanen OP, Kauhanen J, Hakola HP, Salaspuro M Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry. 1996;29(1):27–9. [PubMed: 8852531]
  383. Tollefson GD, Lancaster SP, Montague-Clouse J The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull. 1991;27(2):163–70. [PubMed: 1924664]
  384. Tollefson GD, Montague-Clouse J, Tollefson SL Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone) J Clin Psychopharmacol. 1992;12(1):19–26. [PubMed: 1552035]
  385. Uhl D Acamprosate in alcohol withdrawal. Deutsche Apotheker Zeitung. 1995;135(46):62–3.
  386. Umbricht-Schneiter A, Santora P, Moore RD Alcohol abuse: comparison of two methods for assessing its prevalence and associated morbidity in hospitalized patients. Am J Med. 1991;91(2):110–8. [PubMed: 1867236]
  387. Vazquez JJ, Guillen FJ, Zozaya J, Lahoz M Cyanamide-induced liver injury. A predictable lesion. Liver. 1983;3(4):225–30. [PubMed: 6323909]
  388. Verbanck PMP The pharmacological treatment of alcoholism: from basic science to clinical medicine. Alcohol Alcohol. 1995;30(6):757–64. [PubMed: 8679016]
  389. Viamontes JA Review of drug effectiveness in the treatment of alcoholism. Am J Psychiatry. 1972;128(12):1570–1. [PubMed: 4554403]
  390. Volpicelli JR Naltrexone in alcohol dependence. Lancet. 1995;346(8973):–. [PubMed: 7637475]
  391. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80. [PubMed: 1345133]
  392. Volpicelli JR, Clay KL, Watson NT, O'Brien CP Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry. 1995;56(9):39–44. [PubMed: 7673104]
  393. Volpicelli JR, Rhines KC, Rhines JS, Vopicelli LA, Alterman AI, O'Brien CP Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737–42. [PubMed: 9283509]
  394. Volpicelli JR, Volpicelli LA, O'Brien CP Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol. 1995;30(6):789–98. [PubMed: 8679021]
  395. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152(4):613–5. [PubMed: 7694913]
  396. Weinrieb RM, O'Brien CP Naltrexone in the treatment of alcoholism. Annu Rev Med. 1997;48:477–87. [PubMed: 9046978]
  397. Weninger ME, Leeper E A treatment program for alcoholics. J Tenn Med Assoc. 1976;69(12):849–50. [PubMed: 994492]
  398. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;34(9013):1438–42. [PubMed: 8676626]
  399. Whyte CR, O'Brien PM Disulfiram implant: a controlled trial. Br J Psychiatry. 1974;124(578):42–4. [PubMed: 4595630]
  400. Wilcox RE, McMillen BA The rational use of drugs as therapeutic agents for the treatment of the alcoholisms. Alcohol. 1998;15(2):161–77. [PubMed: 9476962]
  401. Wilde MI, Wagstaff AJ Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53(6):1038–53. [PubMed: 9179530]
  402. Willette RE, Barnett G Narcotic antagonists: naltrexone pharmacochemistry and sustained-release preparations. Rockville, MD: Alcohol, Drug Abuse, and Mental Health Administration; 1981.
  403. Wilson A Disulfiram implantation in alcoholism treatment. A review. J Stud Alcohol. 1975;36(5):555–65. [PubMed: 239278]
  404. Wilson A, Blanchard R, Davidson W, McRae L, Maini K Disulfiram implantation: a dose response trial. J Clin Psychiatry. 1984;45(6):242–7. [PubMed: 6202678]
  405. Wilson A, Davidson WJ, Blanchard R Disulfiram implantation: a trial using placebo implants and two types of controls. J Stud Alcohol. 1980;41(5):429–36. [PubMed: 6157943]
  406. Wilson A, Davidson WJ, Blanchard R, White J Disulfiram implantation. A placebo-controlled trial with two-year follow-up. J Stud Alcohol. 1978;39(5):809–19. [PubMed: 353387]
  407. Wilson A, Davidson WJ, White J Disulfiram implantation: placebo, psychological deterrent, and pharmacological deterrent effects. Br J Psychiatry. 1976;129:277–80. [PubMed: 786421]
  408. Wilson WH, Petrie WM, Ban TA, Barry DE The effects of amoxapine and ethanol on psychomotor skills related to driving: a placebo and standard controlled study. Prog Neuropsychopharmacol. 1981;5(3):263–70. [PubMed: 7267843]
  409. World Health Organization The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva: World Health Organization. 1993.
  410. Wozniak KM, Pert A, Linnoila M Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol. 1990;187(2):287–90. [PubMed: 2272364]
  411. Wright C, Moore RD, Grodin DM, Spyker DA, Gill EV Screening for disulfiram-induced liver test dysfunction in an inpatient alcoholism program. Alcohol Clin Exp Res. 1993;17(1):184–6. [PubMed: 8383924]
  412. Young LM, Haakenson CM, Lee KK, van Eeckhout JP Riboflavin use as a drug marker in Veterans Administration cooperative studies. Control Clin Trials. 1984;5(4 Suppl):497–504. [PubMed: 6394211]
  413. Zernig G, Fabisch K, Fabisch H Pharmacotherapy of alcohol dependence. Trends Pharmacol Sci. 1997;18(7):229–31. [PubMed: 9253852]
  414. Zimberg S Evaluation of alcoholism treatment in Harlem. Q J Stud Alcohol. 1974;35:550–7. [PubMed: 4431894]
Bookshelf ID: NBK32938


  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...